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Objectives:Negativepressurewoundtherapy(NPWT)isausefultherapyintheprepara-
tion of wounds prior to application of asplit-thickness skin graft (STSG) both “pregraft”
and “postgraft” on top of the STSG. Customarily, a foam-based NPWT has been used,
butgauze-basedtherapyisﬁndinganincreasinguse.Gauzeiseasytoapplyandforgiving
of complicated wound geometries so it can be an ideal material in this indication. The
aim of this study was to quantitatively assess the clinical efﬁcacy of gauze-based NPWT
as an adjunctive therapy to STSG procedures. Methods: A prospective, noncompara-
tive, multicenter evaluation was carried out to assess the performance of gauze-based
NPWT. Twenty-one patients had NPWT applied prior to deﬁnitive closure by STSG or
ﬂap techniques (pregraft group). A further 21 patients underwent an STSG procedure
and had gauze-based NPWT placed immediately on top of the STSG (postgraft group).
Negative pressure was applied at −80 mm Hg. Results: In the pregraft group, NPWT
was used for a median of 12 days. Improvement in quality of wound bed with decreased
nonviable tissue (from 20% to 0% median wound area) and increased granulation tissue
(from 20% to 90% median wound area) was observed. In the postgraft group, median
duration of therapy was 5 days at which point median percentage skin graft-take was
96%. Conclusions: Gauze-based NPWT appears to be an effective addition to the care
and management of wounds intended for deﬁnitive closure by STSG.
INTRODUCTION
Negative pressure wound therapy (NPWT) has become widely used in the treatment of a
variety of challenging wounds. One indication where application of NPWT is considered
beneﬁcial is in split-thickness skin graft (STSG) procedures where it can provide a number
ofbeneﬁts.Negativepressurewoundtherapycanbeappliedtothebeneﬁtofgraftprocedures
in 2 distinct stages of the care pathway, described in a series of guidelines presented by the
International Panel on Topical Negative Pressure1 and outlined later.
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First, NPWT can be used to provide rapid wound bed preparation to prepare a wound
bed for grafting. In a wound with a signiﬁcant tissue defect and poor-quality wound bed,
NPWT can be used to reduce the size of the defect, increase the quality of the wound bed
by increasing the amount of granulation tissue, and contribute toward infection control.
Once these goals are achieved, the wound bed may become a good candidate for surgical
placement of an STSG. These positive end-points have been observed in numerous studies
that describe the closure of a variety of wound types by secondary intention,2-4 and the
ability of NPWT to contribute to wound bed preparation.5,6
Second, NPWT can be used in place of a bolster dressing following the application of
anSTSG.AdvantagesofusingNPWTpostgraftingincludeeffectiveremovalofserousﬂuid
thatcanpreventgrafttakeifallowedtoaccumulateunderneaththegraft,betterimmobiliza-
tion of the graft in anatomically challenging areas, and improved close approximation of
thegrafttothewoundbed,especiallywherethewoundbedhasanirregularsurface.Several
clinical studies have been carried out to evaluate the effect of NPWT when applied on top
of an STSG.7-10 These studies were largely carried out using a polyurethane foam-based
NPWTsystemseithercommerciallyavailableorimprovisedkits.Severalcomparativestud-
ies against standard therapy (commonly gauze or bolster dressings) have shown improved
clinical outcomes following the use of NPWT applied on top of an STSG, including im-
proved graft take,7,10 decreased incidence of regrafting procedures,11 decreased length of
hospitalization,7 qualitative appearance of graft,8 and improved healing rates2,10 compared
with conventional therapy or standard bolster dressings.
Negative pressure wound therapy consists of a negative pressure source and a
wound ﬁller material, which until recently has almost exclusively consisted of a porous
polyurethane foam (V .A.C. Granufoam, KCI, San Antonio, Texas). Recently, alternative
commercial suppliers have entered the NPWT market and a choice of wound ﬁller mate-
rials, including antimicrobial gauze, has become available as a result. In vivo studies have
shown that foam and gauze are equally able to transmit negative pressure to the wound
bed and equally efﬁcient in promoting changes in microvascular wound blood ﬂow.12,13
Gauze-based NPWT has been shown to be effective in reducing wound area and volume in
a range of difﬁcult wounds.3
We hypothesized that gauze-based NPWT could be a useful adjunct to the successful
integration of an STSG into the recipient wound bed, in terms of wound bed preparation
and in improving STSG take. Gauze is easy to apply and forgiving of complicated wound
geometries so it could be an ideal material in this indication. We aimed to assess the
effectivenessofgauze-basedNPWTsystemasanadjunctivetherapyinskingraftprocedures
in a prospective, noncomparative clinical evaluation. In particular, we measured the effect
on wound area, depth, and volume and calculated the efﬁciency of take.
MATERIALS AND METHODS
Study design
A prospective, noncomparative multicenter evaluation was carried out to assess the perfor-
mance of gauze-based NPWT in terms of wound progress toward closure wounds deemed
suitable for treatment with NPWT (listed on clinicaltrials.gov; ref NCT00994162). The
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study was performed in accordance with guidelines set forth by the Declaration of Helsinki
and approved by the ethical review boards at all involved institutions. All patients provided
written informed consent prior to enrollment. Exclusion criteria included the presence of
necrotic tissue or more than 25% slough in the wound bed (following removal by debride-
ment these wounds may be eligible), untreated osteomyelitis, malignancy, active bleeding,
exposed blood vessels or organs, and untreated wound infection. In total, 153 patients with
mixedetiologywoundswereassessed.Analysisofthewholepopulationhasbeenpublished
elsewhere.14,15 A subanalysis on a series of STSG patients was carried out and is described
in this report. Wounds healed by STSG were analyzed separately because the clinical out-
comes and end-points in this group of patients were different from the remainder of the
wounds whose wounds progressed by secondary intention.
Delivery of gauze-based NPWT
Gauze-basedNPWTwasdeliveredusingtheEZ-CareorV1STAdevices(Smith&Nephew,
Largo, Florida). These devices were used at a continuous negative pressure of −80 mm Hg.
Antimicrobial gauze (Kerlix-AMD; Tyco, Gosport, United Kingdom), provided as part of
a tailored dressing kit from the manufacturer, was used to transmit negative pressure to the
wound bed using the Chariker-Jeter method of application.16 Wounds were examined and
dressings changed at 2- to 3-day intervals.
Clinical procedures
Patients included in this report were divided into 2 groups according to their care pathway,
referred to in this report as the pre- and postgrafting groups. Because of the retrospective
nature of the data assessment, the 2 groups contained separate patients.
Pregrafting
Patients with wounds of various etiologies with signiﬁcant soft tissue deﬁcit and/or poor-
quality wound bed were treated with gauze-based NPWT prior to placement of an STSG
with the aim of improving the quality of the wound bed and maximizing subsequent STSG
success. This group of patients was identiﬁed retrospectively from the main patient cohort.
All patients who received a graft or a ﬂap following the use of NPWT to prepare the wound
were included in the “pregraft” group. Patients who may have been intended for grafting at
onsetoftherapybutwhowerenotgraftedforanyreasoncouldnotbeidentiﬁedandwerenot
included in the analysis. Wounds were assessed, photographs taken, and dressings changed
typically every 3 days. The following parameters were measured: wound area, depth, and
volume (a function of area and depth); exudate levels (using a 4-point category scoring
system—none, mild, moderate, or heavy) and wound bed tissue (measured by recording the
percentage area of the wound surface composed of red granulation, yellow slough, yellow
ﬁbrous, black necrotic, pink epithelial, and other). Wounds were monitored until they had
progressed sufﬁciently to support the STSG procedure, usually represented by complete
coverage of the wound bed with granulation tissue. The end-point in all patients in this
group was STSG. In isolated cases, gauze-based NPWT was continued postgrafting. In
these cases, only data up to the point at which the graft was placed were assessed.
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Postgrafting
A separate cohort of patients underwent an STSG procedure and had gauze-based NPWT
placed immediately on top of the STSG with the aim of stabilizing the STSG immediately
postgrafting and improving subsequent graft take. These patients were identiﬁed prospec-
tively as a predeﬁned subset of the main clinical evaluation.
A typical procedure was carried out under standard operating room procedures. The
woundareawasdebridedwithascapelto“freshen”thewoundbedpriortograftapplication.
The graft was meshed at a 2:1 ratio and stapled to the wound bed. A layer of Acticoat
(Smith & Nephew, St Petersburg, Florida) was applied to the graft surface followed by
gauze-based NPWT. This dressing remained in place for 4 to 5 days. Upon removal of the
NPWT dressing, the graft site was evaluated to ascertain whether the wound was “healed”
or “progressing toward healing” (a subjective measure based on clinical judgment) and a
separateassessmentoftheapproximatepercentageareaofsuccessfulandunsuccessfulgraft
take was recorded (an objective measure of graft success). Graft sites were subsequently
dressed with Xeroform and a gauze dressing. Patients were assessed in the outpatient clinic
a t5t o7d a y s .
Data assessment
The 2 groups described earlier were assessed separately in all data analysis. Data relating
to patient demographics, comorbidities, wound aetiology, and duration were captured for
all patients. Continuous data were summarized using means and standard deviations where
the data were normally distributed (eg, patient age) and medians and ranges where the data
did not follow a normal distribution (eg, wound duration). Categorical data such as patient
sex were summarized using frequency distributions.
RESULTS
Patient demographics are shown in Table 1. A total of 21 patients were included in the
pregrafting group and a further 21 patients were included in the postgrafting group. Both
groups included a mixed etiology of wound types including acute and chronic conditions.
Results for each group are described separately later.
Pregrafting
Meanpatientagewas51.1years.Medianwounddurationpriortoplacementofgauze-based
NPWT was 2.5 weeks (range, 0–104 weeks) (Table 1).
Following application of gauze-based NPWT, therapy was continued until wounds
were considered suitable for STSG procedure to proceed as determined by the attending
physician.Inparticular,itwasnecessarytoencouragegranulationtissueformationoverex-
posed structures such as exposed tendons. Negative pressure wound therapy was continued
for a median of 12 days (range, 5–59 days).
Wound dimensions were monitored over this period (Table 2). Median wound area
reducedfrom65.6to60.5cm2 inthisgroupofpatients.Wounddepthandvolumedecreased
by a median of 66.7% and 67.3%, respectively,indicatingthat wounds tended to in-ﬁll from
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the bottom up with only a small reduction in wound area over the duration of therapy.
Median weekly percentage reductions in wound depth and volume of 23.4% and 26.6%,
respectively, were calculated.
Table 1. Patient demographics and wound characteristics∗
Pregraft group Postgraft group
N2 1 2 1
Male:female 13:8 16:5
Mean age (range); SD 51.1 (31–74); 14.2 43.2 (20–78); 16.2
Principle comorbidities
Diabetes 23.8% 23.8%
Hypertension 33.3% 14.3%
Original wound etiology
Chronic 5(23.9%) 4 (16.7%)
Traumatic 9 (42.9%) 7 (33%)
Surgical 7 (33%) 6 (28.5%)
Burn 0 3 (14.3%)
Not recorded 0 1(4.2%)
Median wound duration 2.5 (range 0–104) 4.3 (range 0–26)
prior to therapy (weeks)
∗ Patientsweredividedinto2groupsaccordingtotheirpositionsalongtheSTSGcare
pathway and treatment goals. The pregraft group received gauze-based negative pres-
sure wound therapy before grafting to improve the wound bed. The postgraft group
received gauze-based negative pressure wound therapy immediately after grafting to
maximize graft take.
Table 2. Median change in dimensions of wounds treated with gauze-based negative pres-
sure wound therapy prior to STSG (pregraft group) (N = 21)
At onset Immediately % overall % Median reduction
Dimension of therapy prior to grafting reduction per week
Wound area, cm2 65.6 60.5 0 (Mean = 12.6) 0
Wound depth, cm 1.5 0.5 66.7 23.4
Wound volume, cm3 84.8 25.3 67.3 26.6
Analysis of changes in the tissue types present on the wound bed was carried out
(Fig 1). Prior to therapy, a median of 20% of the area of the wound bed contained nonviable
tissue. Although nonviable tissue was deﬁned as the cumulative value for black necrotic,
slough, and ﬁbrotic tissue, in practice because the presence of any black necrotic tissue was
a reason for exclusion, at baseline this value represents slough or ﬁbrotic tissue (median
percentage area of necrotic tissue at baseline was 0%). Only 20% was composed of healthy
granulation tissue. Following gauze-based NPWT, a median value of 90% of the wound
surface was composed of granulation tissue, creating a suitable surface on which to place
an STSG. A reduction in the amount of nonviable tissue was also observed at treatment
discontinuation with a median value of 0% coverage.
When the wound bed was adequately prepared, 15 (75%) of wounds were surgically
closed by STSG and 5 (25%) were closed by ﬂap procedures (data not available for one
wound).
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Figure 1. Percentage area of different tissue types in wounds treated with gauze-based
negative pressure wound therapy prior to STSG (pregraft group). Percentage wound area
consisting of nonviable (necrotic, slough, and ﬁbrous tissue), and granulation tissue, was
assessed at baseline (left-hand side) and at treatment discontinuation (right-hand side).
Bar within gray box represents median, + represents mean, and  represents outliers.
N = 20.
Postgrafting
Clinical outcomes following placement of gauze-based NPWT on top of an STSG were
assessed in a separate cohort of 21 patients. Mean patient age was 43.2 years. Original
wound etiology was mixed (Table 1). Median wound duration prior to graft application
was 4.3 weeks (range, 0–26 weeks) and median wound area was 62.8 cm2 (range, 4.7–
395.8 cm2). Following application of gauze-based NPWT on top of the STSG, median time
to treatment discontinuation was 5 days at which point 95% of patients were healed or
progressing toward healing. One patient (5%) who received a graft to a venous leg ulcer
was not classed as “progressing toward healing” because of the presence of ﬁbrotic tissue
along with the skin graft. This patient did not, however, need a regraft procedure during the
follow-up period.
The degree of graft take was also measured following treatment with gauze-based
NPWT and is shown in Table 3. A median graft take of 96% (range, 40–100) was observed.
Median duration of stay following the grafting procedure was 5 days (range, 1–15 days).
There were no wounds that required regrafting during the study period.
Figure 2 shows case images from a trauma patient who had suffered a fractured
humerus and loss of tissue on upper arm in a motorcycle accident. After 8 days of gauze-
based NPWT, the wound was closed with a split-thickness skin graft and NPWT was
reapplied for an additional 5 days at which point NPWT was discontinued with nearly
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complete graft survival. For purposes of data analysis, this patient was included in the
“pregraft” group.
Table 3. Clinical outcomes following applica-
tion of gauze-based negative pressure wound
therapy on top of STSG∗
Median Range
Graft take (% area) 96 40–100
Length of hospital stay, d 5 1–15
∗N = 19 (data not available for 2 patients).
DISCUSSION
Negative pressure wound therapy has been described as a “bridge” technique for wounds
thatarenotamenabletoimmediateclosurebyeithersecondaryintentionorsurgicalclosure.
The majority of publications describe the use of foam-based NPWT. Here the efﬁcacy of
gauze-based NPWT in this treatment pathway is described for the ﬁrst time. Application
of gauze-based NPWT to “shallow” graft wounds is hypothesized to be easier to apply
because of the highly conformable nature of gauze compared with foam.17 Thus, STSG
may provide the ideal indication for the adoption of gauze-based NPWT.
One of the principal objectives for use of NPWT in STSG care pathway is the devel-
opment of a granulating wound bed before grafting to maximize graft take. In the present
study, a granulating wound bed was achieved within a median of 12 days of NPWT. This
compareswellwithapreviouslypublishedstudyusingfoam-basedNPWTinwhichdiabetic
foot ulcer wounds were also successfullyprepared for ﬂapping or grafting within 11 days,18
signiﬁcantly faster than in control (standard therapy) wounds. Another advantage of using
NPWTbeforegraftingistherapidweeklyreductionof23%inwoundvolume.Itispossible
that the reduction in wound volume induced by NPWT may pave the way from more com-
plex tissue transfers and ﬂap procedures toward simpler, tissue-sparing procedures such as
STSG.5,19 This would have signiﬁcant impact on patient morbidity.
A high graft take rate of 96% was observed following the use of NPWT on top of an
STSG. An identical rate of graft take was reported following 5 days of foam-based NPWT
over grafted radial fore-arm ﬂap donor sites.20 In the present study, no regraft procedures
were required during the study period. A comparative study comparing STSG treated
postoperatively with either NPWT or standard bolster dressings, grafts treated with NPWT
required signiﬁcantly fewer repeat grafting procedures than the control (bolster dressing)
group.11 This implies that gauze-based NPWT may be as efﬁcacious as foam-based NPWT
in this indication as well as potentially being easier to apply.17
This study describes a retrospective assessment of prospectively captured data. The
principal limitation is the lack of a comparator group. Another limitationis that the pregraft
and postgraft groups contained separate groups of patients rather than being composed of
a single cohort of patients who received continuous use of NPWT both before and after
their graft procedure. Negative pressure wound therapy provides a different beneﬁt in the
pregraftphase(whereimprovementofthewoundbedandreductioninwounddimensionsin
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particular are important) compared with the postgraft phase (when the bolstering effect and
ﬂuid handling capability of NPWT are most important). Because these treatment phases
are distinct and well delineated, the use of separate patient cohorts to demonstrate the
utility of NPWT in the overall treatment of patients preparing for and receiving STSG is
valid although not ideal. Future studies should include a single patient group and follow
outcomes during the entire clinical pathway. A further limitation arose from the method of
identifying those patients described in the pregraft group. These patients were identiﬁed by
the fact that they had received an STSG as a deﬁned end-point. All wounds in this group
had therefore improved sufﬁciently to receive an STSG. This study was not able to identify
patients where the initial treatment goal may have been to prepare for STSG but where that
goal was not achieved. This limitation may have potentially skewed the data in favor of
NPWT. Future studies should prospectively identify the treatment goal of applying NPWT
andmeasureoutcomescomparedwiththeproportionofpatientswhoachievedtheirgoal.A
furtherlimitationisinthesubjectivenatureofsomeofthewoundassessmentmeasurements
potentially leading to investigator bias or inter- and intrainvestigator variability.
Currently, application of NPWT over STSG is not considered standard care because
of the additional short-term costs associated with its use. However, an evidence base is
developing to support the use of NPWT in graft sites at risk of loss or breakdown. Grafts
in areas subject to excessive mobility, for example, over a joint11,21 and highly exuding
wounds21 are more susceptible to loss. Older patients or those suffering from diabetes
mellitus are also known to suffer a higher rate of graft loss10,22 and may therefore beneﬁt
more from application of NPWT.
Application of NPWT to all skin graft patients may also facilitate earlier mobilization
thatmayaidrecoveryandcontributetowardfasterhospitaldischarge.Withstandardbolster
dressings the recommendation is that patients are immobilized for approximately 5 days
postoperativelytoreducetheriskofgraftlossasaresultofshearing.7,22 Onelimitingfactor
is the mobility of the NPWT device. Using wall suction as the method of NPWT delivery
reducespatientmobility,whereascommerciallyavailabledevicesmaysigniﬁcantlyimprove
patient mobility. In the present study, the use of gauze-based NPWT allowed some patients
to be discharged much more rapidly than previous STSG procedures would have allowed.
Four patients in this study were discharged with a portable pump from hospital, within
24 hours of the graft procedure and managed as outpatients. No difference in outcomes was
observed compared to patients who were hospitalized for the full 5 days postoperatively.
Further investigation is required to fully appreciate the ﬁnancial implications of offsetting
the costs of therapy against earlier hospital discharge.
The 2 patient groups described in this report represent a holistic care pathway for
treatment of wounds intended for deﬁnitive closure by STSG improved by the addition of
gauze-based NPWT. This study is the ﬁrst published report describing the effective use of
gauze-based NPWT in both the preparation of wounds for STSG and subsequent use as an
advanced bolster dressing to enhance graft take.
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Figure 2. Use of gauze-based negative pressure wound therapy (NPWT) pre- and post-STSG in a
trauma patient. Initial application of NPWT was carried out in the operating room and the wound
assessment and replacement of gauze-based NPWT occurred at 2 days (A, B). After 8 days of
NPWT, the wound was ready for closure with a split-thickness skin graft and NPWT (gauze) was
continued for an additional 5 days (C, D). At day 5 postgrafting, NPWT was discontinued with
nearly complete graft survival (E).
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